Skip to main content
OpenTrials
Completed

NCT Number: NCT02360202

Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid

Clinical observation frequently shows a paradoxical effect of topical corticosteroids in charge of a sudden melting of edema in the first days of treatment, which could be due to mobilization of extracellular. No study has shown the value of this measure in patients treated with topical steroids. This uncertainty, coupled with the observation of the paradoxical effects of topical steroids on edema are some patients that despite the systemic absorption of clobetasol propionate, a salt-free diet is not currently recommended practice.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bullous Pemphigoid Autoimmune Diseases Immune System Diseases Pemphigoid, Bullous Skin Diseases Skin Diseases, Vesiculobullous Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Rouen University Hospital

Rouen, 76031, France

About this study

The main objective of the study is to evaluate whether there is fluid retention after introduction of clobetasol propionate treatment from 10 g/day dosage to 40 g / day in patients with bullous pemphigoid. Bio-impedance is a noninvasive device for measuring with an electric current of low intensity the different volumes of the human body. A preliminary experiment of impedance measurements in some patients with bullous pemphigoid (examination requested as part of a nutritional assessment) showed that these patients had mostly a total water loss without dehydration, corresponding to a significant undernutrition during 1 month of treatment, possibly related to muscle wasting and protein loss by skin erosions without obvious argument for fluid retention, justifying reproduce these measures on a larger number of patients and the other to accurately assess the evolution of nutritional parameters during the first month of treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with age higher than 18
  • Patient with bullous pemphigoid,
  • Patient treated by local corticosteroid therapy (clobetasol propionate cream) but not yet processed or for less than 48 hours,
  • Signed informed consent.
  • Patient affiliated to Social Security Regimen
  • Effective contraception in women of childbearing age (for postmenopausal women, confirmatory diagnosis of menopause will be collected)

Exclusion criteria

  • Concomitant treatment with corticosteroids
  • Recent introduction or recent (<6 weeks) treatment with diuretics, angiotensin-converting enzyme, receptor antagonist or anti-angiotensin renin (aliskiren)
  • contraindication to the use of Clobetasol propionate (DERMOVAL and CLARELUX)
  • Patient on salt diet (<or = to 5 g / d)
  • Patients carry a defibrillator or a pace maker
  • Amputated Patient
  • Pregnant and lactating
  • Patient with Urinary Incontinency
  • Recent heart decompensation in the last 6 weeks
  • known Nephrotic Syndrome
  • known or Severe hepatic impairment
  • Hypoalbuminaemia less than 20 g / l

Treatment and study plan

Impedance analysis

Procedure

Impedance analysis in patient with Bullous pemphigoid disease treated with clobetasol propionate.

impedance analysis includes : fat measures, lean body mass, total body water, extracellular water phase angle

Clobetasol Propionate cream treatment

Drug

clobetasol propionate treatment initiated following French recommendations

Other names: DERMOVAL or CLARELUX cream

Primary outcomes

  1. Change from Baseline in fluid retention at day 30

    Time frame: Day 30

    Change from Baseline in extra-cellular water volume at day 30 measured by bioimpedance analysis

Secondary outcomes

  1. Change from Baseline in fluid retention at day 7

    Time frame: Day 7

    Change from Baseline in extra-cellular water volume at day 7 measured by bioimpedance analysis

  2. Weight variation between day 1 and day 30

    Time frame: Day 30

  3. Urinary Sodium level variation between day 1 and day 30

    Time frame: Day 30

  4. Urinary creatinin level variation between day 1 and day 30

    Time frame: Day 30

  5. Brain Natriuretic Peptide level variation between day 1 and day 30

    Time frame: Day 30

  6. Change from Baseline in nutritional parameters at day 30

    Time frame: Day 30

    bioimpedance analysis, C Reactive Protein level, albumin level, daily diet diary, Buzby index

  7. Change from Baseline in bullous pemphigoid disease severity index at day 30

    Time frame: Day 30

    BPDAI questionary assessment

  8. Change from Baseline in bullous pemphigoid disease severity index at day 7

    Time frame: Day 7

    BPDAI questionary assessment

  9. Change from Baseline in corticoid administration dosage at days 30

    Time frame: Day 30

    Evaluation of corticoid dosage between day 1 and day 30

Sponsors and collaborators

Lead sponsor

University Hospital, Rouen

Other

Collaborators

  • Société de Dermatologie Française

Registry information

Official study title

Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid

Acronym: RECOPB

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Feb 10, 2015
Registry last updated
Feb 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.